Vaxil Bio Ltd.
VXL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 58.83% | 34.48% | 32.55% | 102.68% | 162.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.06% | 31.39% | 17.68% | 30.53% | 55.89% |
| Operating Income | -55.06% | -31.39% | -17.68% | -30.53% | -55.89% |
| Income Before Tax | 649.19% | 422.29% | 469.03% | 53.95% | 34.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 649.19% | 422.29% | 469.03% | 53.95% | 34.83% |
| Earnings from Discontinued Operations | 110.53% | 121.45% | 121.45% | 21.92% | -309.80% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 489.14% | 355.43% | 388.34% | 49.16% | 13.15% |
| EBIT | -55.06% | -31.39% | -17.68% | -30.53% | -55.89% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 472.94% | 336.42% | 350.00% | 49.28% | 13.27% |
| Normalized Basic EPS | -159.82% | 33.20% | 33.77% | 51.70% | 34.88% |
| EPS Diluted | 472.94% | 336.42% | 350.00% | 49.28% | 13.27% |
| Normalized Diluted EPS | -159.82% | 33.20% | 33.77% | 51.70% | 34.88% |
| Average Basic Shares Outstanding | 26.20% | 14.84% | 3.48% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 26.20% | 14.84% | 3.48% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |